drugset / Press release
Breast Cancer New Drug: OBI-822/821 received Taiwan FDA Approval for entering Phase III trial
2012-08-08 · OBI Pharma, Inc · original obipharma.com ↗
Breast Cancer New Drug:OBI-822/821 received Taiwan FDA Approval for entering Phase III trial
The release as fetched from its publisher. obipharma.com ↗